Introduction {#s0001}
============

Immune checkpoint inhibitors are a new form of systemic therapy that "release the brakes" on the immune system, allowing enhanced ability of T cells to specifically target and kill cancer cells. Programmed death receptor 1 (PD-1) is a receptor on T cells that, when activated, sends a signal that inhibits T cell anti-neoplastic activity.[@cit0001] Programmed death receptor ligand 1 (PD-L1) is the cell surface protein that activates PD-1; because it is often expressed on tumor cells, PD-L1 helps promote tumor evasion of the immune system.

Targeting PD-1 with novel antibodies has emerged as a promising anti-neoplastic therapy. Recent studies with anti-PD-1 therapy have demonstrated improved overall survival in various malignancies, including melanoma[@cit0002] and non-small cell lung cancer.[@cit0003] Efficacy of anti-PD-1 therapy activity appears to be correlated with PD-L1 tumor expression. Patients with elevated expression have higher response rates[@cit0004] and improved overall survival[@cit0005] compared to patients treated with chemotherapy. Conversely, patients with low expression have worse outcomes.[@cit0003]^,^[@cit0006]

In soft tissue sarcomas (STS), PD-L1 expression has been found to be relatively low compared to other tumors: in a series from Memorial Sloan Kettering, only 12% of patients (6/50) were found to express PD-L1 \>1%.[@cit0007] Of these 6 patients, 4 had gastrointestinal tumors, 1 had a synovial sarcoma, and 1 had a radiation-induced sarcoma. There was no clear correlation demonstrated between PD-L1 expression and tumor type, size, or grade. In corroboration, a recent study by Torabi, *et al*. demonstrated a lack of PD-L1 expression in liposarcomas, osteosarcomas, chondrosarcomas, and rhabdomyosarcomas.[@cit0008] By contrast, PD-L1 expression rates as high as 34--52% have been reported for other types of tumors.[@cit0009]^,^[@cit0010]

Consistent with low PD-L1 expression, anti PD-1 therapy efficacy in STS also appears to be relatively low: in a prospective study of 38 STS, only 19% of patients had a response.[@cit0011] As a result, relatively few clinical trials investigating immunotherapy agents in STS have been proposed. Methods to increase PD-L1 expression and potentially improve anti PD-1 immunotherapy activity in STS are needed in this under-represented population. In this analysis, we identified pre-operative radiotherapy (RT) as a potential means to increase PD-L1 expression by comparing expression of PD-L1 and other immune biomarkers, before and after RT.

Methods {#s0002}
=======

Patient selection {#s0002-0001}
-----------------

After obtaining IRB approval, patients treated at Emory University School of Medicine for non-metastatic STS between 2005 and 2015 were analyzed. To be included in the study, patients were required to have tissue material for immunohistochemistry from biopsy and surgical resection samples. Two cohorts of patients were included: Cohort 1 consisted of patients who underwent biopsy, pre-operative RT, followed by surgical resection; Cohort 2 consisted of patients who underwent biopsy followed by surgical resection, without any pre-operative RT. Patients who received pre-operative chemotherapy were excluded from this analysis.

All patient charts were reviewed for the following baseline characteristics: age, gender, size, grade, depth, primary tumor histologic subtype, location and receipt of post-operative chemotherapy. RT treatment parameters were also recorded, including total dose, dose per fraction, time from RT to surgical resection.

Treatment {#s0002-0002}
---------

At Emory University, all STS patients are discussed at a multi-disciplinary tumor board, which includes representatives from radiation oncology, surgical oncology, orthopedic surgical oncology, pathology, diagnostic radiology, and medical oncology. Management decisions for surgery and RT were thus made in a joint manner. A dose of 50--50.4 Gy in 25--28 fractions was prescribed for all patients, with the vast majority receiving 50 Gy in 25 fractions. Surgical resection was performed within 8 weeks (2--8 weeks) after completion of RT.

Immunohistochemistry {#s0002-0003}
--------------------

Immunohistochemistry was performed using 5 um thick sections from paraffin-embedded tissue. Antibodies used for staining included PD-L1 (E1L3 N clone; *Cell Signaling*), PD-1 (NAT clone, *Abcam*), and CD8 (C8/144B clone; *Cell Signaling*). Positive PD-L1 expression was defined as staining of the plasma membrane in \>1% of tumor cells. Macrophages\' PD-L1 expression was determined qualitatively only. PD-1 and CD8 expression was defined as staining in \>5% of tumor cells and lymphocytes, respectively.

Statistical analysis {#s0002-0004}
--------------------

Immune biomarker expression levels were directly compared between each patient\'s biopsy and resection sample. Biomarker expression was recorded as a dichotomous variable (yes vs. no). For categorical variables, the Fisher\'s exact test was utilized. All statistical analyses were 2-sided, with p-values \<0.05 considered statistically significant.

Characteristics were compared between patients with PD-L1 expression after RT and patients without expression by Wilcoxon rank-sum test for continuous variables, and Chi square test or Fisher\'s exact test for categorical variables, where appropriate. For time to event analysis, outcomes were measured from date of surgery. Distant metastases were defined as development of disease in another organ, outside of the nearest draining lymph node basin and/or primary tumor location. DM was estimated by the Kaplan--Meier product-limit method; the log-rank test was used to assess for differences between treatment groups. Multivariate analysis (MVA) was performed using the Cox proportional hazards model.[@cit0012] All potentially prognostic covariates were initially entered and a backwards stepwise selection method was employed.[@cit0013] All statistical analyses were performed using SPSS version 22.

Results {#s0003}
=======

Patient and treatment characteristics {#s0003-0001}
-------------------------------------

### Cohort 1 {#s0003-0001-0001}

Forty-six patients with stage II-III STS who received pre-operative RT and had both biopsy and resection samples available for analysis were identified. The median time from completion of RT to surgical resection was 28 days (range: 13--54). Histologic STS subtypes included undifferentiated pleomorphic sarcoma (UPS) (71.7%), liposarcoma (17.4%), leimyosarcoma (6.5%), and 1 each of myxoid, synovial, epitheliod and spindle cell sarcoma. The median patient age was 61.0 years old and 60.9% of patients were male. Most tumors were grade 3 (80.4%), T2b (87.0%), and located in the extremities (84.6%). [Table 1](#t0001){ref-type="table"} summarizes patient baseline and treatment characteristics. Table 1.Baseline patient and treatment characteristics of irradiated patients. (n = 46)Median Age (range) in years61.0 (31.0 -- 85.7)Gender  Male28 (60.9%) Female18 (39.1%)T stage  T1-T1b3 (6.5%) T2 a3 (6.5%) T2b40 (87.0%)Grade  1--29 (19.6%) 337 (80.4%)Histologic Subtypes  Undifferentiated Pleomorphic Sarcoma33 (71.7%) Liposarcoma8 (17.4%) Leiomyosarcoma3 (6.5%) Other4 (8.7%)Tumor Location  Upper Extremity4 (8.8%) Lower Extremity35 (76.1%) Abdomen/Pelvis7 (15.2%)Radiation Dose  50 Gy, 25fractions42 (89.7%) 50.4 Gy, 28 fractions4 (10.3%) Median (Range), in Days, from Last Day of XRT to Surgery28 (13--54)Post-operative Chemotherapy  No39 (84.8%) Yes7 (15.2%)

### Cohort 2 {#s0003-0001-0002}

As described above, five patients with stage II-III STS who underwent post-operative RT were identified to be used as controls. Similar to the pre-operative RT patients, the post-operative RT patients had high grade morphology (100%), high prevalence of UPS (100%), and were located in the extremities (100%).

Immune biomarkers {#s0003-0002}
-----------------

All patients had biopsy and resection samples. For the 46 patients treated with pre-operative RT, the PD-L1 expression at time of biopsy, prior to RT, was 0% in all cases ([Fig. 1c](#f0001){ref-type="fig"} and [1d](#f0001){ref-type="fig"}). On the resected, irradiated sample, PD-L1 expression was elevated in 5 out of 46 patients (10.9%) ([Fig. 1g](#f0001){ref-type="fig"} and [1h](#f0001){ref-type="fig"}). This increase in PD-L1 expression was borderline statistically significant (p = 0.056). [Table 2](#t0002){ref-type="table"} illustrates the characteristics of the 5 patients who had elevated PD-L1 in their irradiated samples. Tumor associated macrophage (TAM) expression of PD-L1 was associated with a statistically significant increase (p = 0.003) from prior to RT (15.2%, 7/46) to after RT (45.6%, 21/46) ([Fig. 1](#f0001){ref-type="fig"}). PD-1 expression was similar between biopsied and irradiated samples (30.9%, 30.9%, p = 1.00), as was expression of levels on CD8-positive lymphocytes (33.3% vs. 28.2%, p = 0.806). Figure 1.PD-L1 expression in undifferentiated pleomorphic sarcoma pre (A-D) and post (E-H) radiation therapy. Prior to radiation therapy, tumor cells and tumor associated macrophages are negative for PD-L1 (C-D). After radiation therapy, both tumor cells (straight arrows) and macrophages (curved arrows) are positive for PD-L1. A, C, E, G: 10x; B, D, F, H: 40x. Table 2.Characteristics of 5 patients with increased PD-L1 expression after pre-operative radiation therapy.GenderAgeLocationT stageGradeHistologic SubtypeTime Between Pre-Op RT & Sx (days)Total Dose% PDL1 staining at biopsy% PDL1 staining at surgery/after RTMale36Lower LimbT2b3Epitheliod2650 Gy/ 25 fx0\> 1Male41Lower LimbT2b3UPS2750 Gy/ 25 fx0\> 1Female60Lower LimbT2b3UPS3550 Gy/ 25 fx0\> 1Male56Lower LimbT2b3UPS1750 Gy/ 25 fx0\> 1Female70Lower LimbT2b3UPS4250 Gy/ 25 fx0\> 1[^2]

Of the patients who received post-operative RT, all biopsy and all resection samples did not demonstrate PD-L1 expression on tumor; PD-L1 expression on TAM did not change: 1/5 (20%) expressed PD-L1 on the unirradiated biopsy sample and 1/5 (20%) expressed on the resected, unirradiated sample.

Clinical outcomes {#s0003-0003}
-----------------

For all patients, median follow up was 69.8 months. Fifteen patients ultimately developed DM. Median time to DM was 11.9 months (0.9-43.7). Twelve patients developed lung metastases; three patients developed liver metastases. Twenty-one patients (45.6%) had elevated PD-L1 TAM expression after RT, while 25 (54.3%) patients did not. Patients with positive PD-L1 expression on TAM were similar in baseline characteristics to patients with PD-L1 negative tumors ([Table 3](#t0003){ref-type="table"}). [Fig. 2](#f0002){ref-type="fig"} illustrates that patients with elevated PD-L1 expression on TAM following RT were associated with lower freedom from DM (at 3 years, 49.7% vs. 87.8%, p = 0.006). On univariate analyses, two other factors were significant for DM: histologic subtype (p = 0.091) and receipt of adjuvant chemotherapy (p = 0.008). Table 3.Baseline characteristics of patients with PD-L1 positive and negative expression on tumor-associated macrophages. PD-L1 positive (n = 21)PD-L1 negative (n = 25) Median Age (years)58.961.0p = 0.721Gender    Male11 (52.4%)16 (64.0%)  Female10 (47.6%)9 (36.0%)p = 0.550T stage    T1 a-T1b1 (4.8%)2 (8.0%)p = 0.673 T2 a1 (4.8%)2 (8.0%)  T2b19 (90.4%)21 (84%) Grade    1--24 (19.1%)7 (28.0%)p = 0.514 317 (80.9%)18 (72.0%) Histologic Subtypes    Undifferentiated Plemorphic Sarcoma14 (66.7%)18 (72.0%)p = 0.755 Liposarcoma5 (23.8%)3 (12.0%)  Leimyosarcoma2 (9.5%)1 (4.0%)  Other0 (0%)3 (12.0%) Tumor Location    Upper Extremity1 (4.8%)2 (8.0%)p = 0.429 Lower Extremity19 (90.4%)20 (80%)  Abdomen/Pelvis1 (4.8%)3 (12.0%) Post-operative Chemotherapy    Yes4 (19.1%)3 (12.0%)p = 0.880 No17 (80.9%)22 (88.0%) Days from Completing XRT to surgery    Median (range)28 (13--42)28 (18--54)p = 0.373 Figure 2.Comparing distant metastases free survival, via Kaplan-Meier plots, between sarcoma patients who express and do not express PD-L1 on macrophages after pre-operative radiation therapy.

On MVA, only TAM PD-L1 expression remained a predictor for DM (Negative staining vs. positive staining; HR 0.16, 95% CI 0.034-0.72, p = 0.017; receipt of adjuvant chemotherapy demonstrated a trend (no chemotherapy vs. receipt of chemotherapy; HR 0.19, p = 0.066). On analysis for overall survival, PD-L1 expression was not a significant predictor on univariate analyses.

Discussion {#s0004}
==========

STS is rare among malignancies in that the usual treatment paradigm grants the capacity to study changes in PD-L1 expression with RT: patients first undergo biopsy, followed by RT, and ultimately surgical resection.[@cit0014] In this novel study, PD-L1 expression was compared between matched non-radiated (n = 5) and irradiated (n = 46) STS samples. At baseline, no PD-L1 expression was demonstrated on tumor samples. On matched irradiated samples, PD-L1 expression was elevated in some instances: 10.9%, p = 0.056. Furthermore, irradiated samples were associated with higher PD-L1 expression on TAM: with increase from 15.2% to 45.7%, p = 0.003. Control samples, from STS patients treated without pre-operative RT, were not associated with any change in PD-L1 expression. Patients who had elevated PD-L1 expression on TAM after RT had lower freedom from DM (at 3 years, 49.7% vs. 87.8%, p = 0.006); PD-L1 also continued to predict for higher DM on MVA.

PD-L1 is a molecule found on tumor an antigen presenting cells. Its function includes sending an inhibitory signal to suppress the immune anti-neoplastic response. This inhibitory milieu may allow tumor cells to escape and allow for the development of distant metastases. Kim *et al* investigated PD-L1 expression in STS[@cit0015]; to assess PD-L1, they used an antibody clone H-130. Similar to our findings, they found that STS patients with PD-L1 expression were associated with lower event free survival. Conversely, in a study utilizing the DAKO antibody (clone 22C3), D\'Angelo *et al* found no correlation of PD-L1 expression and clinical outcomes.[@cit0007] Our study used a third antibody -- clone E13LN. It seems likely that differences in the antibody specificity, affinity, and/or epitptopes may contribute to the differences in correlation between expression and clinical outcomes.[@cit0016] There are two major important differences between our study and those by Kim[@cit0015] and D\'Angelo[@cit0007] that may contribute to our findings. First, our STS patient population was very specific: we included only stage II and III STS patients who did not receive pre-operative chemotherapy. Second, our analysis found a significant correlation between PD-L1 expression in tumor samples that had been irradiated and the development of DM in tumor samples that had been irradiated. If these findings were to be are validated in prospective samples, using multiple antibodies, it would present PD-L1 as a possible biomarker to stratify patients for possible anti-PD-1/PD-L1 therapy. Finally, it should be noted that we were not able to proceed with analysis correlating tumor PD-L1 expression and clinical outcomes because of the low numbers of patients (n = 5, 10.9%) who were ultimately PD-L1 positive after RT (n = 5, 10.9%).

With growing evidence that PD-L1 is one biomarker for efficacy of anti PD-1 therapy, researchers have investigated methods to enhance PD-L1 expression as a method to increase response rates with PD-1 therapy. In preclinical studies using cell lines and mouse models, RT has been shown to increase tumor PD-L1 expression.[@cit0017]^,^[@cit0018] RT appears to induce increased MHC1 mediated antigen presentation and increased tumor lymphocyte infiltration. This radiation response appears partially modulated by increased expression of interferon-Y[@cit0019]; in response to these radiation effects, tumors are hypothesized to increase PD-L1 in order to evade immune recognition. Furthermore, acquired resistance to PD-1 inhibitors can occur via mutations to apelin receptor (APLNR)[@cit0020] and interferon-receptor--associated Janus kinase 1 (*JAK1)*,[@cit0021] both of which lead to decreased interferon-Y expression and tumor infiltration by immune cells. Our study builds on these pre-clinical studies by providing the first evidence in human STS samples, that RT modulates PD-L1 expression, which may suggest a potential response to PD-1 therapy. Recently, a secondary analysis of a prospective study found that patients treated with RT and PD-1 inhibitor pembrolizumab had improved outcomes relative to patients treated with pembrolizumab alone.[@cit0022] Taken together, these data contribute ideological support to clinical trials investigating addition of RT to improve the efficacy of PD-1 inhibitor therapy.

This present study has both weaknesses and strengths. The analysis is limited given it is based on samples that were identified retrospectively, introducing possible selection bias. The matched control arm is also a small sample size due to our institutions\' preference to utilize pre-operative RT for stage II-III STS. Pre-clinical evidence suggests that PD-L1 expression peaks 3 days after RT, and then begins to decline.[@cit0017] Based on this preclinical response, our analysis of PD-L1 expression at median of 28 days after completion of RT may be suboptimal. Nonetheless, PD-L1 expression was still elevated at this later time point. In spite of these limitations, this study examined a relatively homogenous patient population, particularly in terms of radiation dose. In addition, patients who received pre-operative chemotherapy were excluded, thus eliminating potential confounding factors that may modulate PD-L1 expression. Finally, the direct comparison of biomarker expression between pre- and post-RT provides new insight into potential strategies to optimize anti-PD-1 therapies for the treatment of STS.

In conclusion, both tumor cell and TAM expression of PD-L1 in STS is significantly increased after RT compared to pre-RT samples. In light of PD-L1 being a biomarker for PD-1 immunotherapy, these novel findings give further support that adding RT may improve efficacy of agents that target the PD-1/PD-L1 immune cascade. We eagerly await the results from the SARC study that is adding a PD-1 inhibitor with standard course RT (50 Gy in 25 fraction) for non-metastatic STS.
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